Rockwell Medical (RMTI) Expected to Announce Earnings on Thursday

Rockwell Medical (NASDAQ:RMTI) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $18.5820 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 26, 2026 at 8:00 AM ET.

Rockwell Medical Stock Performance

NASDAQ:RMTI opened at $1.03 on Wednesday. The stock has a market capitalization of $40.58 million, a PE ratio of -6.44 and a beta of 1.71. Rockwell Medical has a fifty-two week low of $0.78 and a fifty-two week high of $2.10. The company has a fifty day moving average of $1.01 and a two-hundred day moving average of $1.06. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.50 and a current ratio of 3.91.

Institutional Investors Weigh In On Rockwell Medical

A number of institutional investors and hedge funds have recently modified their holdings of RMTI. XTX Topco Ltd grew its holdings in Rockwell Medical by 286.5% in the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after buying an additional 46,029 shares during the period. Jane Street Group LLC acquired a new position in Rockwell Medical during the fourth quarter valued at approximately $84,000. Geode Capital Management LLC grew its stake in Rockwell Medical by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock worth $304,000 after buying an additional 41,668 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Rockwell Medical by 12.3% in the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after acquiring an additional 148,737 shares in the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on RMTI. HC Wainwright reissued a “buy” rating and issued a $2.50 price target on shares of Rockwell Medical in a research note on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rockwell Medical in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $2.50.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.